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Introduction
A recent cohort study carried out among outpatients in a mental 
health care setting showed that outpatients suffering from an anxiety 
disorder whose treatment adhered to the available clinical-practice 
guidelines had greater symptom reduction after one year, compared 
to patients whose treatment did not adhere to these guidelines [1]. 
However, some patients remain non-responsive to treatment, even 
when their treatment was found to adhere to the guidelines and despite 
the fact that they were able to receive multiple recommended evidence-
based treatments. The ability to identify such patients before treatment 
begins is an important challenge in clinical practice. The ability to do so 
could lead to improvement of the guidelines at a more individualized 
level, which would directly benefit patients.
Recently [2] provided an overview of what is known about factors 
that influence non-adherence and non-response in anxiety disorder 
patients receiving either antidepressant medication or cognitive-
behavioural interventions. Based on the existing literature, they 
suggest that factors relevant to predicting treatment outcome include: 
low treatment motivation, hidden secondary motives for seeking 
treatment, encountering barriers that hamper treatment attendance 
(e.g. transportation problems or difficulties arranging for childcare), 
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pre-treatment symptom severity and the presence and severity of 
possible comorbid psychopathology [2]. Many of these factors have 
been investigated as part of intervention studies examining the effects 
of monotherapies. In these studies patients were randomly allocated to 
an experimental condition or a control condition. Therefore patients 
lacked the opportunity to select a treatment of their own choice. 
This may adversely affect the generalizability of the findings to daily 
practice. None of the studies mentioned by Taylor et al. [2] investigated 
the influence of all of the above-mentioned factors, in concert, on 
treatment outcome. Thus, the question of what the predictive power 
of these prognostic factors, alone or in combination, would be on the 
treatment outcome for the patient is still operative.
Abstract
Background: Several countries have developed guidelines for anxiety disorders containing algorithms that 
summarize the recommended treatment steps for these disorders. It is important to know which patients have a poor 
prognosis for treatment according to such algorithms.
Aims: To investigate the predictive power of variables known to be able to influence treatment prognosis in situations 
where practice guidelines for anxiety disorders are adhered to.
Method: To study the predictive power of variables that are known to be able to influence treatment prognosis, 81 
patients who participated in a guideline implementation study and whose treatment was found to adhere to available 
guidelines were selected. Using logistic regression analysis two models were constructed: one to predict treatment non-
response; another to predict persistent functional impairments at the 1-year follow-up.
Results: The final prediction model for treatment non-response contains only gender and secondary gain variables. 
It appears that: males have a higher likelihood (p=.074), and patients that report hopes of obtaining external benefits 
by seeking treatment have a lower likelihood (p=.054) of showing treatment non-response at the 1-year follow-up. The 
discriminatory power of this model was found to be poor, however. The model for persistent functional impairments 
includes gender, satisfaction with the accessibility of healthcare services and the presence of a comorbid anxiety 
disorder. It appears that: males (p=.87) and patients who express dissatisfaction with the accessibility of care (p=.008) 
have a higher likelihood, and that; patients who suffer from an additional comorbid anxiety disorder have a lower 
likelihood (p=.079) of persistent functional impairments. The discriminatory power of this model is excellent.
Conclusion: It remains difficult to predict which anxiety disorder patients will not benefit from treatment that is 
tailored according to available practice guideline recommendations, therefore no one should be prevented from being 
offered such treatment, if one removes barriers in attending treatment.
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A systematic review of the prognostic factors of long term disability 
in mental disorders performed by Cornelius et al. [3] sheds light on 
some additional factors. In this review strong evidence was found for 
age as a relevant factor for continuous disability. Limited evidence 
was found for gender, education, unemployment, and socioeconomic 
status in general. Also, a patient’s cultural background should be 
considered an additional putative factor predicting non-response and 
continuous disability, especially because of established higher drop-out 
rates from general mental health treatment for ethnic minorities in the 
Netherlands [4].
The aim of the present study is to investigate the predictive value 
of the factors described above in predicting non-response and long-
term disability. In the present study these factors will be explicitly 
studied in conjunction with one another. The context of this study is an 
outpatient clinical setting where treatment is optimized according to 
the available evidence-based treatment guidelines, and where patients 
were encouraged to choose their own preferred methods of treatment.
Method 
Study participants and procedure
The present study used data collected as part of a study that 
investigated the feasibility and effectiveness of adhering to clinical-
practice guidelines for anxiety disorders in secondary mental health 
care [1,5]. This study was approved by the medical ethics committee of 
the VU University Medical Centre Amsterdam. Detailed information 
about study design and measurement procedures can be found in the 
two aforementioned references. A general description of the relevant 
research procedures is given here.
A cohort for the study was formed of patients who were registered 
at the community mental health care centre in Almelo, the Netherlands, 
after the implementation of the Dutch multidisciplinary practice 
guidelines for anxiety disorders was begun [1,5]. For the present study 
we included patients aged 18 years or older who i) were diagnosed 
with a primary DSM-IV diagnosis of panic disorder with/without 
agoraphobia, social phobia, obsessive compulsive disorder (OCD), 
generalized anxiety disorder (GAD), posttraumatic stress disorder 
(PTSD), specific phobia or hypochondriasis; ii) gave written informed 
consent for participation, and iii) received treatment according to 
the Dutch anxiety disorder guidelines recommendations (see: www.
ggzrichtlijnen.nl). Co-morbidity with other mental disorders was 
allowed.
In order to maintain representativeness, only two exclusion criteria 
were used for the current study: (1) a primary clinical diagnosis of a 
psychiatric disorder other than one of the anxiety disorders described 
above; and (2) not being fluent in Dutch since language difficulties 
would harm the validity and reliability of the data collected.
Investigated practice guidelines and measure of adequate 
guideline adherence
The Dutch multidisciplinary guidelines for anxiety disorders 
contain recommendations for both psychotherapy (mainly cognitive 
behavioural therapy, but also EMDR for PTSD) and pharmacotherapy 
(mainly selective serotonin reuptake inhibitors or serotonergic tricyclic 
antidepressants). These options are counted as equally valid.
A review of each participating patient’s medical file was used to 
establish whether treatment had actually been delivered according to 
the guideline algorithms, originally yielding a proportion of patients 
who had been receiving recommended care that was classified according 
to the following labels: “adherent”, “non-adherent” and “inapplicable” 
[1]. The medical files were reviewed by specially developed process 
indicators. A checklist was used to score the different indicators [5]. 
Ultimately, if an algorithm was followed correctly and all the necessary 
steps in the treatment had been taken, the case would receive the label 
“adherent.” If a single necessary treatment step in the algorithm had not 
been properly applied because of a failure on the part of the responsible 
health care provider, the case would receive the label “non-adherent.” 
If none of the treatment steps appeared to be applicable, the case would 
receive the label ‘inapplicable’ overall. For the present study only the 
‘adherent’ cases were included for further analyses [1]. Measurements 
relevant to treatment outcome were performed at baseline and at a 
1-year follow-up.
Study Measures
Primary outcome measures
We sought to construct two models to predict non-response 
with respect to clinical symptoms and to functional limitations. (i) 
Clinical symptoms were measured with the Symptom Checklist 
(SCL90-R) [6]. A patient’s overall score on the SCL90-R reflects his 
or her general level of psychopathology (range 0–360). Non-response 
was operationalized as not showing reliable change on the SCL90-R 
total score from baseline to 1-year follow-up, according to the Reliable 
Change Index (RCI) criteria defined by Jacobson and Truax [7]. 
Applied to the SCL90-R total score, this means that reliable change 
on the SCL90-R is indicated by a score of at least 30 points. Thus, all 
cases with a change score of less than 30 points were defined as non-
responders. (ii) To assess functional impairments at baseline and at the 
1-year follow-up the Sheehan Disability Scale (SDS) [8] was used. This 
patient-rated measure asks the subject to rate on a scale ranging from 
1 (“not at all”) to 10 (“extremely”): 1) the extent to which symptoms 
have disrupted work/school work; 2) the extent to which symptoms 
have disrupted social life/leisure activities, and 3) the extent to which 
symptoms have disrupted family life/home responsibilities. The sum 
of the scores on these three subscales yields the SDS total score (range 
3 to 30), and provides a general impression of the level of functional 
impairment experienced by the patient. The persistence of functional 
impairment was also defined dichotomously. A patient with an SDS 
total score of 6 or higher at the 1-year follow-up was considered to 
suffer from persistent functional impairments. In the literature on 
anxiety disorders an SDS total score of 5 or less has been used to signal 
functional recovery [9,10].
Predictors
Demographic variables
The patients’ gender and age were derived from the medical 
files. Patients were asked to report their country of birth and also 
the birth countries of both of their parents, their educational level, 
employment status and monthly net income. In the present study a 
patient is considered to have a foreign background if at least one of 
his or her parents was born outside the Netherlands or its former 
colonies. Ultimately, the patients’ educational level was operationalized 
dichotomously, as having completed only primary education (yes/no). 
This where the level of education in the cohort of patients studied was 
already relatively low on average. It was hypothesized that reaching 
adequate treatment effect when adhering to the guidelines, would be 
especially challenging in patients that only finished elementary school 
at best.
Citation: Van Dijk MK, Verbraak MJPM, Oosterbaan DB, Hoogendoorn AW, van Balkom AJM (2014) Predictors of Non-response and Persistent Functional 
Impairments in Treatment Adhering to Evidence-based Practice Guidelines for Anxiety Disorders. J Depress Anxiety 3: 159. doi:10.4172/2167-
1044.1000159
Page 3 of 7
Volume 3 • Issue 3 • 1000159J Depress AnxietyISSN: 2167-1044 JDA an open access journal
Assessment of DSM-IV axis I disorders
The presence of a DSM-IV axis I disorder was assessed by the 
Mini International Neuropsychiatric Interview (M.I.N.I.) [11,12], 
administered by a trained clinician as part of the standardized intake 
procedure at the community mental health care center. In patients with 
co-morbid mental disorders the primary diagnosis was defined as the 
psychiatric disorder associated by the patient with the greatest degree 
of suffering. In determining the influence on treatment outcome 
and persistent functional impairments, the presence of a comorbid 
secondary anxiety disorder, and the influence of a comorbid depressive 
disorder were separately investigated.
Psychiatric status variables
The Personality Diagnostic Questionnaire-4+ was used as a screener 
for the presence of comorbid DSM-IV axis II personality disorders, 
at baseline [13,14]. The PDQ4+ is a self-administered, true/false 
screening questionnaire. The PDQ4+ total score, the sum of the scores 
of the individual items, can be used as an index of overall personality 
disturbance (range 0-99), with a total score of 30 or higher indicating 
a substantial likelihood that the subject has a significant personality 
disturbance [15]. This 30 point cut-off value was used as a dichotomous 
measure for the absence or presence of personality disturbance.
To assess patient motivation the Nijmegen Motivation List 2 
(NML2) was administered at baseline [16]. Only the preparedness 
subscale (range: 10 to 60) of the NML2, which consists of 10 items that 
express the patient’s preparedness to actively invest in treatment and 
to make sacrifices for the sake of treatment, was investigated for its 
predictive value on treatment outcome. Research has shown this NML2 
subscale to be the most significantly related to treatment outcome in 
outpatient mental health care of the subscales in the NML2 [16]. 
Secondary gain was operationalized in accordance with the DSM-
IV definition of “obtaining external benefit” (APA, 1994; p. 453). 
Patients were explicitly asked to indicate whether special support and 
mediation by therapists was expected (yes/no) and the aspects for 
which they expected support and mediation. Patients could tick the 
following items, where appropriate: job, social security claims, budget 
for getting help from relatives, financial problems, compensation 
for unusual healthcare costs, legal/police matters, accommodation, 
insurance, other.
To assess practical barriers that could hamper treatment attendance 
the item from the Dutch version of the World Health Organization 
Quality Of Life questionnaire (WHOQOL-BREF) [17] was used and 
administered at baseline. This item asks the patient to rate on a scale 
ranging from 1 (“very dissatisfied”) to 7 (“very satisfied”), their degree 
of satisfaction with the accessibility of the health services. In order to 
facilitate interpretation, ultimately this variable was also dichotomized. 
Scores ranging from 1 to 4 were recoded to 1, indicating that the patient 
was less than satisfied with the accessibility of the healthcare services. 
Scores 5 to 7 were recoded to 0, indicating that the patient was satisfied 
or very satisfied with the accessibility of the health services used.
Statistical Analyses
Standard descriptive statistics were used to describe the study 
population. To check whether attrition bias posed a threat to the 
validity of the study results differences between study completers 
and study drop-outs, t-tests for continuous variables and χ2 tests 
for proportions were used on the original (i.e. non-imputed) data. 
Ultimately, missing data resulting from patients dropping out of the 
study were handled by using multiple imputation by chained equations 
(MICE), which operates under the assumption that given the variables 
used in the imputation procedure, the missing data are Missing At 
Random (MAR). There were three sets of variables selected for the 
imputation model [18]: all variables that appeared in the complete data 
model, all variables that related to dropping out of the study, and all 
variables that related to the two main outcome variables (the severity 
of psychiatric symptoms (SCL90-R) at follow-up measurement and 
the score for functional impairment (the Sheehan Disability Scale). 
Data imputations were performed with chained equations method in 
Stata 12.1 using predictive mean matching (PMM) as the imputation 
method with 20 imputations.
All final analyses were carried out on the multiple imputed data 
set, using all cases originally included in the study that were judged 
to have been adequately treated according to the guideline algorithms 
(guideline adherent; n=81). In constructing a prediction model for 
“non-response” and “functional impairment” we used a model-
building strategy called “purposeful selection of covariates” [19]. After 
a careful bivariate analysis of each independent variable, retaining any 
variable whose bivariate test has a significance level below 0.25 (step 
1), a multivariate model is fitted (step 2) retaining all variables with 
significance levels below 0.10, checking that none of the coefficients 
changed markedly in magnitude (i.e. ∆β>20%) and re-entering a 
predictor if necessary in order to prevent such a change (step 3), and 
finally evaluating the possible addition of each independent variable 
individually (step 4). Non-linearity (step 5) and interaction effects (step 
6) are evaluated, and ultimately the “final model” obtained is evaluated 
in terms of model fit by pseudo R-square and “area under the receiver 
operating characteristic (ROC) curve” (step 7) The basic statistical 
calculations in this study were performed with SPSS, version 17.0 
(SPSS Inc., Chicago IL, US). The multiple imputations and analyses 
using logistic regression on the imputed data were performed using 
Stata 12.1 (Stata Corp., College Station TX, US).
Results
As can be seen from the flowchart (Figure 1), 81 patients from the 
group initially included in the study were recommended for treatment 
according to the treatment guidelines and were judged to have received 
such treatment (guideline adherent cases). The attrition rate of patients 
in this group at the 1-year follow-up was 16%. Tables 1 and 2 present 
demographic and clinical characteristics, respectively, of the 81 
adherent cases and characteristics of the study completers vs. patients 
lost to follow-up.
As shown in Tables 1 and 2, the proportion of males was higher in 
the group of patients who were lost to follow-up compared with the 
study completers. Furthermore, patients lost to follow-up were less 
educated than study completers and were less motivated to complete 
treatment. Moreover, somewhat more patients lost to follow-up were 
diagnosed with a social phobia.
At the 1-year follow-up the estimated overall percentage of non-
responders on the SCL90-R among patients whose treatment adhered 
to the guidelines was 40%, while 63% experienced persistent functional 
impairments.
Table 3 depicts the results of the bivariate analyses as a sub-step 
of the study analyses and the final results of the procedure using the 
multivariate logistic regression analyses, performed with non-response 
as the dependent variable.
As shown in Table 3, only the “gender” and “secondary gain” 
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variables were associated with non-response measured with the 
SCL90-R. Patients that at baseline
reported hopes to obtain external benefits by seeking treatment, 
appear to have a lower chance of showing non-response to treatment 
as measured at 1-year follow-up when looking at the final results of 
the multivariate regression analyses (p=.054). This while males tend to 
have a higher chance of showing non-response (p=.074). No interaction 
effects were found.
However, the fit statistics for this model are low: Mc Fadden’s 
pseudo R-square equals 0.07 and ROC=0.66, which indicates that the 
discrimination between responders and non-responders based on this 
model is rather poor. Table 4 presents the results of the bivariate and 
multivariate analyses with persistent functional impairments measured 
with the SDS as the dependent variable.
As shown in Table 4, the variables of “satisfaction with accessibility 
of health services”, “gender” and “presence of comorbid anxiety 
disorder” were associated with persistent functional impairments. 
The results show that when comparing patients that express being 
less than content with the accessibility of care, with patients that 
express being content or even more satisfied with the accessibility, 
the first group has a higher chance of showing persisting functional 
impairments at 1-year follow-up. A result that is highly significant 
(p=.008). Also, males tend to have a higher chance of persisting 
functional impairments as measured at 1-year follow-up (p=.087). 
Surprisingly, compared to patients without such comorbid condition, 
patients who were at baseline found to suffer from another comorbid 
anxiety disorder appear to have a lower chance of persisting functional 
impairments (p=.079). Again, no interaction effects were found. The 
fit statistics for this model, predicting functional impairment based on 
these three predictor variables, are quite good: Mc Fadden’s pseudo 
R-square equals 0.30 and ROC=0.82, indicating an excellent degree of 
discrimination between patients with and without persistent functional 
impairments as measured at the 1-year follow-up.
To further study the results with respect to the predictive value 
of “gender”; “secondary gain” and “presence of a comorbid anxiety 
disorder”, we compared baseline scores on the SCL90-R of the predictor 
variables. It was found that males scored significantly lower on the 
SCL90-R at baseline than females (mean total score= 173.56 versus 
mean total score= 203.60; t=-2.52, df=78.88, p=.014). Also, patients 
who at baseline reported their hope of obtaining external benefits 
by seeking treatment scored significantly higher on the SCL90-R at 
 
Eligible for inclusion in the 
cohort study  
n = 236 
 
Informed consent 
n = 181 (76.7%) 
 
 
Completed baseline 
questionnaires 
n = 160 (88.4%) 
 
 
 
Guideline applicable 
n = 139 (86.9%) 
 
 
 
 
Guideline-adherent 
n = 81 (58.3%) 
 
 
 
 
1-year follow-up 
n = 68 (84.0%) 
 
 
 
Refusals: n= 55 (23.3%) 
 
 
 
Non-fluent in Dutch: 
n= 21 (11.6%) 
 
 
Guideline inapplicable 
n = 21 (13.1%) 
Reasons: 
Diagnosis revised: n= 9 
Early therapy drops out: 
n= 12 
 
 
Guideline-non-adherent 
n = 58 (41.7%)
Figure 1: Flow chart for patient inclusion. 
*significant difference p<.05, ** significant difference p<.01, § difference p<.1 a Excluded pairwise from further analysis
Table 1: General characteristics of the study sample of completers and patients lost to follow-up (original data).
Total Sample
(n=81)
Study completers 
(n=68)
Patients lost to 
follow-up (n=13)
P-values between group 
differences: Study completers 
vs. Patients lost to follow-up
Age: Mean (SD) 33.5 (11.9) 33.49 (11.4) 33.62 (15.2) .972
Gender (male): n (%) 29 (33.8) 20 (29.3) 9 (69.2) .006**
Foreign background (yes): n (%) 11 (13.6) 8 (11.8) 3 (23.1) .275
Educational level; only primary school or less: n (%) 11(13.6) 7 (10.3) 4 (30.8) .048*
Unemployed (yes): n(%) 38 (46.9) 30 (44.8) 8 (61.5) .268
Missing item values: n 1a 1a 0a
Net monthly income in Euros: mean (SD) 877.4 (602.7) 914.3 (611.4) 723.4 (562.8) .329
Missing item values: n 19a 18a 1a
NML2 preparedness score: mean (SD) 47.4 (8.1) 48.2 (7.6) 43.3 (9.6) .059*
Secondary gain(yes): n (%) 33 (40.7) 27 (41.5) 6 (50.0)
Missing item values: n(%) 3a 2a 1a
Satisfaction with accessibility of health care services: mean (SD) 3.7 (.7) 3.7 (.7) 3.9 (.7) .341
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baseline, compared to the patients who did not (mean= 211.62 vs. 
mean= 179.38; z=-2.39, p=.017; calculations based on the imputed 
data). Baseline severity scores were found to be significantly related to 
symptom severity at the 1-year follow-up (r= .479, p<.001). Differences 
in baseline symptom severity thus might be a relevant confounding 
factor when studying the relationship between gender, secondary gain 
and treatment (non-)response.
Additional analyses of the results on functional impairment did not 
reveal differences on the SDS on the predictor variables of “gender”, 
“comorbid anxiety disorder” and “accessibility of health care services”, 
suggesting no confounding due to baseline differences.
Discussion
This practice-based study examined the predictive value of 
variables that are known to be able to influence treatment prognosis 
in anxiety disorder patients. These variables were examined in concert 
in a sample of 81 patients treated in a specialized mental health care 
setting who were judged to have been adequately treated according 
to evidence-based guidelines. We tried to develop a prediction model 
that allowed the identification of patients who run the risk of showing 
treatment non-response or who will continue to experience functional 
§difference p<.1
a Excluded pairwise from further analysis
Table 2: Clinical characteristics of the study sample of completers and patients lost to follow-up (original data).
Total Sample 
(n=81)
Study completers
(n=68)
Patients lost to 
follow-up (n=13)
P-values between Group differences: Study 
completers vs. Patients lost to follow-up
Primary diagnosis: n (%)
Panic disorder 31 (38.3) 27 (39.7) 4 (30.8) .54
Social phobia 16 (19.8) 11 (16.2) 5 (38.5) .064§
OCD 7 (8.6) 6 (8.8) 1 (7.7) .894
GAD 6 (7.4) 5 (7.4) 1 (7.7) .966
PTSD 16 (19.8) 14 (20.6) 2 (15.5) .666
Specific phobia 3 (3.7) 3 (4.4) 0 (0.0) .999
Hypochondria 2 (2.5) 2 (2.9) 0 (0.0) .999
Comorbid axe I Diagnosis (yes): n (%) 30 (37) 27 (39.7) 3 (23.1) .255
Total number of axe I diagnoses: mean (SD) 1.41 (.6) 1.4 (.6) 1.2 (.4) .150
Comorbid anxiety disorder (yes): n (%) 9 (11.1) 9 (13.2) 0 (0.0) .164
Comorbid mood disorder (yes): n (%) 17 (21.0) 14 (20.6) 3 (23.1) .840
PDQ-4 score; personality disorder probable (yes): n (%) 29 (35.8) 27 (43.5) 2 (20.0)b .159
Missing item values: n 9a 6a 3a
SCL90R total-score: mean(SD) 192.8 60.8 195.7 (63.1) 177.9 (46.1) .336
Treatment drop-out: n (%) 23 (28.4) 19 (27.9) 4 (30.8) .836
Table 3: Predictors of non-response on the SCL90R (change score less than 30 
points), with estimated values based on the imputed dataset (n=81).
Determinants Bivariate Multivariate
Odds 
ratio 95% CI p
Odds 
ratio 95% CI p
Age in years 1.03 0.99-1.07 .211 X
Gender (male vs. female) 2.18 0.78-6.12 .139    2.80 0.91-8.66 .073
Background (foreign vs. 
native) 2.12 0.53-8.49 .289 X
Having completed only 
primary school or less (yes 
vs. no)
1.22 0.28-5.38 .789 X
Employment status (unem-
ployed vs. employed) 0.59 0.23-1.58 .298 X
Net monthly income in Euros 1.00 0.99-1.001 .783 X
NML2 preparedness score 0.96 0.90R-1.02 .215 X
Secondary gain (yes/no) 0.42 0.15-1.18 .100   0.33 0.11-1.02 .054
Satisfaction with accessibil-
ity health care services: (less 
than satisfied vs. satisfied or 
very satisfied)
1.57 0.59-4.18 .365 X
Comorbid anxiety disorder 
present (yes/no) 0.73 0.17-3.18 .671 X
Comorbid mood disorder 
present (yes /no) 0.57 0.16-1.97 .370 X
PDQ-4 score; personality 
disorder probable (yes/no) 0.67 0.24-1.85 .434 X
Table 4:  Predictors of persistent functional impairments (a total score of 6 or higher 
on the Sheehan Disability Scale at 1-year follow-up), with estimated values based 
on the imputed dataset (n=81).
Determinants Bivariate Multivariate
Odds 
ratio 95% CI p
Odds 
ratio 95% CI p
Age in years 1.05 0.99-1.11 .067    X
Gender (male vs. female) 2.68 0.84-8.53 .096 3.84 0.82-17.89 .087
Background (foreign vs. 
native) 0.82 0.17-3.94 .800     X
Having completed only 
primary school or less 
(yes vs. no)
4.06 0.45-36.62 .212 X
Employment status 
(unemployed vs. 
employed)
0.81 0.28-2.34 .699 X
Net monthly income in 
Euros 1.00 0.99-1.001 .463 X
NML2 preparedness 
score 0.97 0.91-1.04 .436 X
Secondary gain (yes/no) 1.02 0.36-2.87 .972 X
Satisfaction with 
accessibility of health 
care services: (less than 
satisfied vs. satisfied or 
very satisfied)
18.29 2.49-134.56 .004 27.84 2.38-325.46 .008
Comorbid anxiety 
disorder present (yes/no) 0.26 0.05-1.33 .105 0.11 0.01-1.29 .079
Comorbid mood disorder 
present (no /yes) 1.77 0.47-7.21 .423 X
PDQ-4 score; personality 
disorder probable 
(yes/no)
1.33 0.46-3.89 .600 X
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impairments when being provided guideline concordant care.
Of the demographic variables considered (age, gender, foreign 
background, educational level, employment status and income) only 
gender was identified as a potentially relevant predictor variable for 
both treatment non-response and persistent functional impairments. 
Males had a higher chance of showing treatment non-response and 
also a higher chance of having persistent functional impairments at the 
1-year follow-up. However, males were found to have lower baseline 
symptom severity scores than females which might explain the results 
pertaining to treatment non-response. The data suggest that gender as 
a predictor of persistent functional impairments may have something 
to do with a subgroup of males quitting treatment prematurely. Of the 
patient characteristics, hope of secondary gain and the presence of a 
comorbid anxiety disorder were identified as being potentially relevant 
to treatment prognosis.
Contrary to what was expected from prior research [20-22], 
patients who reported a hope of gaining external benefits actually had 
a lower chance of showing treatment non-response. These patients 
were found to suffer from more severe general psychopathology at 
the baseline. It may be that the reported motives for secondary gain 
might reflect a genuine need for help in managing life. This suggests 
that as long as additional support is available in addition to the regular 
evidence-based care for anxiety disorders, for example the availability 
of a community psychiatric nurse, greater treatment effects can be 
achieved in these patients. Patients who suffered from a comorbid 
anxiety disorder at baseline were also found to have a lower likelihood 
of persistent functional impairments. On the other hand, patients who 
were less than satisfied with the accessibility of health care services 
had a substantially greater risk of persistent functional impairments. 
Actually, this was the only study result that was significant when 
maintaining the orthodox significance level of 5 percent and therefore 
probably the most relevant result.
There are some limitations to the results of the current study. One of 
the most important issues is the relatively small sample size used in this 
study. In addition, because of the small sample size and the explorative 
nature of our study we maintained a liberal significance level of .10 
for the selection of predictors. This makes replication of our study 
necessary. The small sample size may explain why the results for some 
of the predictors of treatment prognosis identified as relevant in other 
studies failed to reach significance in the current study. While this may 
be true, the size of the estimated Odds Ratio’s in our study does suggest 
however that the influence of these variables is probably not very 
strong. This is likely to be especially true in a situation where patients 
get to choose among recommended evidence-based treatment options 
and can also receive multiple evidence-based treatments at the same 
time, as is the case in everyday clinical practice, as opposed to the more 
controlled circumstances of most predictor studies. Another limitation 
of the current study might be the fact that the treatment results were 
measured only at the 1-year follow-up. Some of the variables studied 
may have predictive value when studied over a shorter time period. The 
one-year time period for measuring treatment results was chosen in this 
prediction study on guideline concordant care because one year is the 
minimum length of time for the main recommended treatment steps 
to be put in effect for most anxiety disorders, in order to determine if 
there has been a sufficient treatment response.
There are several strengths to the present study. The patients 
included in the study sample are representative of “real world” mental 
health care. There were almost no exclusion criteria. To our knowledge 
the study presented here is also the first to look at the conglomerate 
of possible predictors of treatment response that have been identified 
as relevant to predicting treatment prognosis (Taylor et al., 2012; 
Cornelius et al., 2011) at the same time. This was done in a setting 
where patients were able to choose among several available evidence-
based treatment options and were also able to receive a combination 
of treatments when the clinician adhered to treatment guidelines for 
anxiety disorders.
From the results of the present study it can be concluded that it is 
hard to predict which anxiety disorder patients will or will not profit 
from guideline-adherent treatment in terms of demonstrating adequate 
treatment response. Unfortunately, this means that for the time being 
selecting an effective cure for the individual patient will for the most 
part remain a process of trial and error.
 However, we may also conclude that with the knowledge 
currently available no one suffering from an anxiety disorder as a 
primary diagnosis should be prevented from being offered some form 
of evidence-based care according to the available evidence-based 
treatment guidelines, if one adapts to gender and removes barriers in 
attending treatment.
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